Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03203330 · ClinicalTrials.gov registry record · Phase 3
A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee
A Phase 3 study of Degenerative Osteoarthritis, sponsored by Kolon TissueGene.
- Active
- Registry status
- Phase 3
- Development phase
- 535
- Enrollment target
- 20
- Study locations
NCT03203330: Active Phase 3 study of Degenerative Osteoarthritis, sponsored by Kolon TissueGene.
NCT03203330 is a Phase 3 study of Degenerative Osteoarthritis that is active but no longer recruiting, run by Kolon TissueGene. The registered enrollment target is 535 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03203330, a Phase 3 study of Degenerative Osteoarthritis, is active but no longer recruiting, sponsored by Kolon TissueGene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 535 participants
- Enrollment target
- 20
- Study locations
Study Summary
A randomized, double-blind, placebo-controlled, multi-center, phase 3 study to determine the safety and efficacy of TG-C in subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee, Osteoarthritis Research Society International (OARSI) medial joint space narrowing (JSN) Grade 1 or 2 of the knee joint. TG-C is to be administered by a single intra-articular injection to the damaged joint area via ultrasound guidance. Patients will be followed for 24 months for safety and efficacy.
Primary Outcome
Assessment of change from baseline in target knee function using the WOMAC Osteoarthritis Index. The WOMAC is a proprietary set of standardized questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee including pain, stiffness, and physical functioning of the joints. The response to the questions is in the form of a checked box associated with the response; None, Mild, Moderate, Severe and Extreme.
Conditions Studied
Interventions
- BIOLOGICAL TG-C
- BIOLOGICAL Placebo Control
Study Locations (20)
Florida
- David Billmeier - Daytona Beach
- Mercedes Ponce De Leon - Miami
- Aurelio Torres-Consuegra - Miami
- Edgar Gonzalez - Miami
- Cathy Barnes - New Port Richey
- Howard Chipman - Oldsmar
- Richard Linn - Sunrise
- Anand Patel - Winter Park
California
- Diraj Karnani - Apple Valley
- Dan La - Covina
- Scott Hacker - La Mesa
- Eric Grigsby - Napa
- Arthur Mabaquiao - San Diego
- Timothy Davis - Santa Monica
- Tien-I Su - Whittier
Alabama
- Jeffrey Davis - Birmingham
- Bradly Goodman - Birmingham
Arizona
- Saima Chohan - Phoenix
- Nebojsa Skrepnik - Tucson
District of Columbia
- Mehul Desai - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 535 participants |
| Start Date | 2018-10-30 |
| Est. Completion | 2026-07-10 |
| Phase | Phase 3 |
What the registry record for NCT03203330 still lists
NCT03203330 is an interventional study that assigns participants to a tested intervention. The registered 535 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% lower).
The record links to 1 condition, with Degenerative Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which TG-C is the first listed.
NCT03203330 names 20 study sites across 5 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT03203330 about?
NCT03203330 is a clinical study titled "A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee". A randomized, double-blind, placebo-controlled, multi-center, phase 3 study to determine the safety and efficacy of TG-C in subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee, Osteoarthritis Research Society International (OARSI) medial joint space narrowing (JSN) Grade 1 or...
What is the current status of trial NCT03203330?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 535 participants. The study started on 2018-10-30. Estimated completion is 2026-07-10.
What conditions does trial NCT03203330 study?
This clinical trial studies the following conditions: Degenerative Osteoarthritis.
What interventions are being tested in trial NCT03203330?
The interventions under investigation include: TG-C (BIOLOGICAL), Placebo Control (BIOLOGICAL).
Who is sponsoring clinical trial NCT03203330?
This trial is sponsored by Kolon TissueGene, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03203330 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Degenerative Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03203330's enrollment target sits among peer trials
535 702nd of 2000 higher than 1,299 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT07091617 · 535 participants · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI